TP53 and cancer: Currently, as an imperative step forward in cancer therapy, different molecule drugs targeting MDM2-p53 which are in the clinical trials stage could restore p53 antitumor activity by preventing the MDM2-P53 interaction in solid and hematologic tumors (68).